Acadia Healthcare (ACHC) director awarded 6,625 shares in equity grant

Rhea-AI Filing Summary

Cancelmi Daniel J reported acquisition or exercise transactions in this Form 4 filing.

Acadia Healthcare Company, Inc. director Daniel J. Cancelmi received a grant of 6,625 shares of common stock as equity compensation. The shares were awarded at no cash cost and are held directly. They will vest over a three-year period in equal annual installments beginning on March 12, 2027, so Cancelmi must remain eligible over time to receive the full amount. Following this grant, he holds 6,625 shares of Acadia Healthcare common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cancelmi Daniel J

(Last) (First) (Middle)

ACADIA HEALTHCARE COMPANY, INC.

4020 ASPEN GROVE DRIVE, SUITE 900

(Street)

FRANKLIN TENNESSEE 37067

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acadia Healthcare Company, Inc. [ ACHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/12/2026		A		6,625(1)	A	$0.00	6,625	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares will vest over a 3-year period in equal annual installments beginning March 12, 2027.

	/s/ Brian Farley as Attorney in Fact for Daniel J. Cancelmi	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Acadia Healthcare (ACHC) director Daniel J. Cancelmi report on this Form 4?

Daniel J. Cancelmi reported receiving a grant of 6,625 shares of Acadia Healthcare common stock. The award was recorded as an acquisition with no cash price per share, reflecting equity-based compensation rather than an open-market purchase or sale.

How many Acadia Healthcare (ACHC) shares did Daniel J. Cancelmi acquire in this transaction?

He acquired 6,625 shares of Acadia Healthcare common stock. These shares were granted as a stock award, not bought in the market, and represent his entire reported direct holding following the transaction, according to the Form 4 data.

What is the vesting schedule for Daniel J. Cancelmi’s 6,625 Acadia Healthcare (ACHC) shares?

The 6,625-share award will vest over three years in equal annual installments. Vesting begins on March 12, 2027, meaning one-third of the shares vest each year from that date, subject to the award’s continued-service conditions.

Did Daniel J. Cancelmi pay a price per share for the Acadia Healthcare (ACHC) stock grant?

No, the reported price per share is 0.0000, indicating a compensation grant rather than a purchase. The shares were awarded as part of his director compensation, not acquired through an open-market transaction.

How many Acadia Healthcare (ACHC) shares does Daniel J. Cancelmi own after this Form 4 transaction?

After the reported grant, Cancelmi directly holds 6,625 shares of Acadia Healthcare common stock. The Form 4 lists these as his total direct holdings following the transaction, with no derivative positions disclosed.